CN101252917A - 适于每日以单剂量形式给药的胍法辛药物制剂/组合物 - Google Patents

适于每日以单剂量形式给药的胍法辛药物制剂/组合物 Download PDF

Info

Publication number
CN101252917A
CN101252917A CNA2006800313902A CN200680031390A CN101252917A CN 101252917 A CN101252917 A CN 101252917A CN A2006800313902 A CNA2006800313902 A CN A2006800313902A CN 200680031390 A CN200680031390 A CN 200680031390A CN 101252917 A CN101252917 A CN 101252917A
Authority
CN
China
Prior art keywords
dosage
guanfacine
auc
maximum
last
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800313902A
Other languages
English (en)
Chinese (zh)
Inventor
A·H·朔贾尔
M·潘尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire LLC
Original Assignee
Shire LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37668083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101252917(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire LLC filed Critical Shire LLC
Publication of CN101252917A publication Critical patent/CN101252917A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2006800313902A 2005-07-28 2006-07-27 适于每日以单剂量形式给药的胍法辛药物制剂/组合物 Pending CN101252917A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70298205P 2005-07-28 2005-07-28
US60/702,982 2005-07-28

Publications (1)

Publication Number Publication Date
CN101252917A true CN101252917A (zh) 2008-08-27

Family

ID=37668083

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800313902A Pending CN101252917A (zh) 2005-07-28 2006-07-27 适于每日以单剂量形式给药的胍法辛药物制剂/组合物

Country Status (18)

Country Link
US (1) US20070048371A1 (https=)
EP (1) EP1909766B1 (https=)
JP (2) JP5726401B2 (https=)
KR (1) KR20080041669A (https=)
CN (1) CN101252917A (https=)
AR (1) AR054595A1 (https=)
AU (1) AU2006275718B8 (https=)
BR (1) BRPI0615989B8 (https=)
CA (1) CA2616181C (https=)
DK (1) DK1909766T3 (https=)
ES (1) ES2566395T3 (https=)
IL (1) IL188980A0 (https=)
NO (1) NO20081038L (https=)
NZ (1) NZ565649A (https=)
RU (1) RU2435573C2 (https=)
TW (1) TW200744672A (https=)
WO (1) WO2007016284A2 (https=)
ZA (1) ZA200801575B (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102498094A (zh) * 2009-09-15 2012-06-13 夏尔有限责任公司 胍法辛的前药
CN102525983A (zh) * 2010-12-31 2012-07-04 北京万全阳光医药科技有限公司 胍法新缓释片及其制备方法
CN102579381A (zh) * 2012-03-30 2012-07-18 河南中帅医药科技发展有限公司 盐酸胍法辛缓释制剂及其制备方法
CN102791258A (zh) * 2010-02-03 2012-11-21 图必制药公司 雷沙吉兰的延迟释放制剂及其用途
CN103298455A (zh) * 2010-06-11 2013-09-11 希拉有限责任公司 赖氨酸安非他命与缓释胍法辛的联合治疗

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120041068A1 (en) * 2010-08-11 2012-02-16 Aptapharma, Inc. Extended Release Pharmaceutical Preparations for Active Pharmaceutical Ingredients with pH Dependent Solubility
US9180104B2 (en) 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
CN105188677A (zh) * 2013-03-13 2015-12-23 特瑞斯制药股份有限公司 苯佐那酯调释固体片剂和胶囊剂
WO2016089997A1 (en) 2014-12-02 2016-06-09 Yale University Methods of preventing neurodegeneration of association cortex in a mammal
PE20181521A1 (es) * 2015-12-08 2018-09-24 Ardea Biosciences Inc Composicion farmaceutica que comprende un potente inhibidor de urat1
JP6656670B2 (ja) * 2016-03-11 2020-03-04 国立大学法人 鹿児島大学 抗ｈｃｖ活性を有する薬剤
US10251857B2 (en) * 2016-04-20 2019-04-09 New Frontier Labs, Llc Azelaic acid esters in the treatment of insulin resistance
WO2019136224A1 (en) * 2018-01-05 2019-07-11 Shire Human Genetic Therapies, Inc. Amphetamine-guanfacine combinations for treatment of neuropsychiatric disorders
JP7814869B2 (ja) * 2021-09-01 2026-02-17 東和薬品株式会社 グアンファシン製剤
JP7835098B2 (ja) * 2022-04-15 2026-03-25 ニプロ株式会社 グアンファシン含有徐放性製剤
EP4292587A1 (en) 2022-06-15 2023-12-20 Sawai Pharmaceutical Co., Ltd. Guanfacine hydrochloride containing pharmaceutical preparation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH649918A5 (de) * 1981-07-09 1985-06-28 Sandoz Ag Verwendung von n-amidino-2-phenylacetamiden als wirkstoff zur herstellung von pharmazeutischen zubereitungen gegen schizophrenie.
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5854290A (en) * 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
DE19834573A1 (de) * 1998-07-31 2000-02-03 Bayer Ag Doppelmetallcyanid-Katalysatoren für die Herstellung von Polyetherpolyolen
FR2781152B1 (fr) * 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
PE20001396A1 (es) * 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
US6635277B2 (en) * 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
EP1355633B1 (en) * 2001-12-19 2005-01-19 AstraZeneca AB NEW FILM COATING containing an ethyl acrylate/methyl methacrylate copolymer and polyvinyl acetate
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
DE60322371D1 (de) * 2002-03-29 2008-09-04 Alza Corp Volumensparende arzneiform zur kontrollierten freisetzung
US6763509B2 (en) * 2002-09-26 2004-07-13 Sun Microsystems, Inc. Method and apparatus for allocating decoupling capacitor cells
US20070104782A1 (en) * 2005-07-28 2007-05-10 Ibrahim Melissa E Modified release tablet formulations with enhanced mechanical properties

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102498094A (zh) * 2009-09-15 2012-06-13 夏尔有限责任公司 胍法辛的前药
CN102791258A (zh) * 2010-02-03 2012-11-21 图必制药公司 雷沙吉兰的延迟释放制剂及其用途
CN102791258B (zh) * 2010-02-03 2018-05-08 图必制药公司 雷沙吉兰的延长释放制剂及其用途
CN103298455A (zh) * 2010-06-11 2013-09-11 希拉有限责任公司 赖氨酸安非他命与缓释胍法辛的联合治疗
CN102525983A (zh) * 2010-12-31 2012-07-04 北京万全阳光医药科技有限公司 胍法新缓释片及其制备方法
CN102579381A (zh) * 2012-03-30 2012-07-18 河南中帅医药科技发展有限公司 盐酸胍法辛缓释制剂及其制备方法
CN102579381B (zh) * 2012-03-30 2013-07-10 河南中帅医药科技发展有限公司 盐酸胍法辛缓释制剂及其制备方法

Also Published As

Publication number Publication date
BRPI0615989A2 (pt) 2011-05-31
ES2566395T3 (es) 2016-04-12
WO2007016284A2 (en) 2007-02-08
RU2435573C2 (ru) 2011-12-10
CA2616181C (en) 2015-02-17
DK1909766T3 (en) 2016-04-04
AR054595A1 (es) 2007-06-27
EP1909766A2 (en) 2008-04-16
BRPI0615989B8 (pt) 2021-05-25
AU2006275718B2 (en) 2012-10-04
JP5726401B2 (ja) 2015-06-03
AU2006275718A1 (en) 2007-02-08
AU2006275718A8 (en) 2012-11-01
RU2008102911A (ru) 2009-09-10
EP1909766B1 (en) 2016-03-16
NO20081038L (no) 2008-04-23
JP2009502951A (ja) 2009-01-29
ZA200801575B (en) 2008-12-31
CA2616181A1 (en) 2007-02-08
KR20080041669A (ko) 2008-05-13
BRPI0615989B1 (pt) 2020-05-26
IL188980A0 (en) 2008-08-07
AU2006275718B8 (en) 2012-11-01
WO2007016284A3 (en) 2007-03-29
US20070048371A1 (en) 2007-03-01
TW200744672A (en) 2007-12-16
JP2012229253A (ja) 2012-11-22
NZ565649A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
CN101252917A (zh) 适于每日以单剂量形式给药的胍法辛药物制剂/组合物
US6476006B2 (en) Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
KR101413613B1 (ko) 약 염기성 선택성 세로토닌 5-ｈｔ3 차단제와 유기산을 포함하는 약물 전달 시스템
US20080286356A1 (en) Pharmaceutical compositions containing terbinafin and use thereof
AU2002321249A1 (en) Pharmaceutical compositions containing terbinafin and use thereof
JPH07258085A (ja) アルフゾシン塩酸塩を含む徐放性製剤
AU761441B2 (en) Sustained release formulation
CN106456611B (zh) 用于治疗恶心、呕吐或腹泻症状的恩丹西酮缓释固体制剂
US20100285119A1 (en) Multiparticulate Extended Release Pharmaceutical Composition Of Carbamazepine And Process For Manufacturing The Same
US20090155358A1 (en) Pharmaceutical compositions of short-acting hypnotic agents in modified-release forms and the procedures to prepare the mentioned formulation
US20050013860A1 (en) Controlled release potassium chloride tablets
NZ207768A (en) Sustained release tablets comprising dipyridamole
HK1119400A (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
Tomuta et al. In vitro-in vivo evaluation of a novel drug delivery system for colonic targeting
HK40056549A (en) Therapeutic compositions for treatment of human immunodeficiency virus
HK1232432A1 (en) Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms
HK1067299B (en) Pharmaceutical compositions containing terbinafine and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1119400

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080827